**Supplementary Table 3. Unadjusted incidence of infection by organ class**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | Etanercept | Infliximab | Adalimumab | Rituximab | Tocilizumab | Certolizumab |
| Number of patients | 8,630 | 4,908 | 7,818 | 5,101 | 2,174 | 1,446 |
| Follow-up time (years) | 15,314 | 8,829 | 13,071 | 5,910 | 1,963 | 1,685 |
|  | **Incidence by infection class per 100 patient years** |
| Sepsis/Bacteraemia(95% CI) | 0.15(0.10, 0.23) | 0.14(0.08, 0.24) | 0.16(0.10, 0.25) | 0.44(0.30, 0.64) | 0.31(0.14, 0.68) | 0.12(0.03, 0.47) |
| Respiratory(95% CI) | 1.82(1.61, 2.04) | 2.25(1.96, 2.59) | 2.28(2.04, 2.55) | 2.71(2.32, 3.16) | 3.16(2.46, 4.05) | 1.72(1.20, 2.48) |
| Skin(95% CI) | 1.31(1.14, 1.51) | 1.21(1.00, 1.46) | 0.89(0.74, 1.06) | 0.90(0.69, 1.17) | 1.38(0.94, 2.01) | 0.42(0.20, 0.87) |
| Gastrointestinal(95% CI) | 0.50(0.40, 0.63) | 0.51(0.38, 0.68) | 0.38(0.29, 0.50) | 0.58(0.41, 0.81) | 0.76(0.46, 1.27) | 0.18(0.06, 0.55) |
| Bone/Joint(95% CI) | 0.67(0.55, 0.81) | 0.43(0.31, 0.59) | 0.51(0.40, 0.65) | 0.49(0.34, 0.71) | 0.46(0.24, 0.88) | 0.53(0.28, 1.03) |
| Genitourinary(95% CI) | 0.61(0.50, 0.75) | 0.48(0.35, 0.64) | 0.68(0.55, 0.84) | 0.81(0.61, 1.08) | 0.46(0.24, 0.88) | 0.36(0.16, 0.79) |
| Other Infection(95% CI) | 0.36(0.28, 0.47) | 0.25(0.16, 0.38) | 0.41(0.31, 0.53) | 0.32(0.21, 0.50) | 0.41(0.20, 0.81) | 0.30(0.12, 0.71) |

CI – Confidence intervals